Needle-free Treatments for Autoimmune Disorders from Switzerland

27/01/2017 - 1 minute

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases.


BioLingus Logo

City: Hergiswill, Switzerland

Founded: 2014

Employees: 1-10

Financial data: N/A

Related Content

Yves Decadt BioLingus CEO
Yves Decadt, CEO

Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory diseases, such as diabetes, Crohn’s and celiac disease. Its therapies are delivered under the tongue or via the nose instead.

Comment: BioLingus is working on oral vaccines against flu and the tropical disease leishmaniasis, tablets for children with type 1 diabetes and an oral version of AstraZeneca‘s diabetes drug exenatide. Its most ambitious project is an oral therapy for rheumatoid arthritis to compete with AbbVie’s Humira, the top-selling drug, as well as Janssen’s Remicade and Amgen’s Enbrel. Together, they make over €19B ($20B) in sales annually.

 

ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member